Funding deal secures Denmark first batches of Bavarian Nordic's Covid-19 vaccine

When and if Bavarian Nordic's fully developed and approved Covid-19 vaccines begin trickling out from its facility, the Danish government has secured first pick, according to documents detailing the deal that MedWatch has read.

Photo: Bavarian Nordic / PR

The Danish government has secured itself a place first in line when Bavarian Nordic's potential Covid-19 vaccine is distributed. This comes as a result of the funding deal struck between the two parties in fall of this year.

Under the terms of the deal, the Danish Ministry of Health has the right – but not the obligation – to claim the first doses from an approved vaccine developed by Bavarian Nordic and produced in its Danish facility.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs